ASCO Annual Meeting 2026, taking place May 29–June 2 at McCormick Place in Chicago, Illinois, with online access, will showcase a wide spectrum of innovative immunotherapy strategies across solid tumors. The program is expected to highlight biomarker-driven treatment approaches, novel combination regimens integrating targeted therapy and checkpoint blockade, next-generation immune-activating platforms, and maintenance strategies in molecularly defined populations.
This article highlights key abstracts across multiple tumor types—including gastric and gastroesophageal junction cancers, HPV-associated malignancies, pancreatic cancer, urothelial carcinoma, and melanoma—featuring phase 2 and translational studies presented in Rapid Oral Abstract Sessions. These trials reflect the ongoing evolution toward precision-guided immunotherapy, tumor microenvironment modulation, and multi-mechanistic combination strategies with the potential to inform future standards of care.
Perioperative tislelizumab plus chemotherapy versus chemotherapy in MHC-II positive/MHC-II negative locally advanced GC/GEJC
A notable abstract to be presented in the Developmental Therapeutics—Immunotherapy track (Rapid Oral Abstract Session) will explore a biomarker-driven approach to perioperative immunotherapy in gastric cancer.
Led by First Author and Presenter Xiangdong Cheng, MD, from Zhejiang Cancer Hospital, this prospective, randomized, open-label phase 2 trial evaluates tislelizumab plus chemotherapy versus chemotherapy alone in patients with locally advanced gastric cancer (GC) and gastroesophageal junction cancer (GEJC).
A key feature of this study is stratification by MHC-II status (MHC-II–positive vs MHC-II–negative tumors), reflecting a growing shift toward immune phenotype–guided treatment selection in the perioperative setting.
Abstract Details
- Session Type: Rapid Oral Abstract Session
- Session: Developmental Therapeutics—Immunotherapy
- Citation: J Clin Oncol 44, 2026 (suppl 16; abstr 2513)
About the Therapy: Tislelizumab
Tislelizumab is a humanized anti–PD-1 monoclonal antibody engineered to optimize immune activation.
Its mechanism includes:
- PD-1 pathway blockade → restores T-cell–mediated anti-tumor activity
- Enhanced T-cell persistence → supports sustained immune responses
- Fcγ receptor minimization → reduces macrophage-mediated T-cell clearance, a potential resistance pathway
Why This Abstract Stands Out
This study highlights several key directions in modern immuno-oncology:
- Perioperative immunotherapy expansion in GI malignancies
- Beyond PD-L1: exploration of MHC-II as a predictive biomarker
- Mechanism-driven immunotherapy design to overcome resistance
Together, these elements position this trial as part of the broader transition toward precision-guided perioperative immunotherapy in GC/GEJC.
Tislelizumab (Tevimbra): Uses in Cancer, Side Effects, Dosage, Expectations, and More
Evaluation of the combination of regorafenib + avelumab in patients with HPV-associated cancer: The phase II REGOMUNE study.
This upcoming abstract will be presented by First Author and Presenter Sophie Cousin, MD, from Institut Bergonié, during the Developmental Therapeutics—Immunotherapy Rapid Oral Abstract Session.
The study is part of the REGOMUNE program, a multicenter, prospective, open-label phase Ib/II trial evaluating the combination of regorafenib and avelumab across multiple advanced solid tumors. The ASCO presentation focuses specifically on the HPV-associated cancer cohort, requiring molecular confirmation of p16-positive disease.
Abstract Details
- Meeting: 2026 ASCO Annual Meeting
- Session Type: Rapid Oral Abstract Session
- Session: Developmental Therapeutics—Immunotherapy
- Citation: J Clin Oncol 44, 2026 (suppl 16; abstr 2517)
- Full Abstract Release: May 21, 2026 (5:00 PM EST)
Study Concept
REGOMUNE explores a combination strategy targeting both tumor biology and the immune microenvironment:
- Regorafenib → inhibits angiogenic and oncogenic kinases, modulating tumor vasculature and stromal signaling
- Avelumab → blocks PD-L1, restoring T-cell–mediated anti-tumor immunity
This dual approach is designed to enhance immune responsiveness by making the tumor microenvironment more permissive to immunotherapy.
Why This Abstract Matters
- Focus on HPV-associated cancers, a biologically distinct and immunogenic subgroup
- Represents a tumor-agnostic, multi-cohort development strategy
- Highlights the growing role of TKI + immunotherapy combinations
- Reflects efforts to overcome resistance through microenvironment modulation
Randomized Phase II Trial of Olaparib and Pembrolizumab vs Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations: SWOG S2001
This upcoming abstract will be presented by First Author and Presenter Vincent Chung, MD, from City of Hope Comprehensive Cancer Center, during the Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Rapid Oral Abstract Session.
This randomized phase II study evaluates maintenance therapy with olaparib plus pembrolizumab versus olaparib alone in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) harboring germline BRCA1/2 mutations, following response or disease control on platinum-based chemotherapy.
Abstract Details
- Meeting: 2026 ASCO Annual Meeting
- Session Type: Rapid Oral Abstract Session
- Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
- Citation: J Clin Oncol 44, 2026 (suppl 16; abstr 4012)
- Full Abstract Release: May 21, 2026 (5:00 PM EST)
Study Concept
This trial builds on prior evidence that PARP inhibition may synergize with immunotherapy:
- Olaparib → induces DNA damage and genomic instability in BRCA-mutated tumors
- Pembrolizumab → restores T-cell–mediated anti-tumor immunity
Preclinical and early clinical data suggest that PARP inhibition can:
- Increase PD-L1 expression
- Activate the STING pathway
- Enhance tumor immunogenicity
Together, this provides a strong rationale for combining PARP inhibitors with checkpoint blockade in DNA repair–deficient pancreatic cancer.
Why This Abstract Matters
- Focuses on a molecularly selected population (gBRCA1/2 mPDAC)
- Explores maintenance immunotherapy strategies after platinum response
- Builds on the foundation of the POLO trial, which established olaparib in this setting
- Aims to define whether adding immunotherapy improves durability of response
Top 10 Pancreatic Cancer Updates – January 2026
Interim Analysis Results from Duravelo-2: Zelenectide Pevedotin (BT8009) + Pembrolizumab in Patients with Previously Untreated Locally Advanced/Metastatic Urothelial Carcinoma
This upcoming abstract will be presented by First Author and Presenter Yohann Loriot, MD, PhD, from Gustave Roussy / University Paris-Saclay, during the Genitourinary Cancer—Kidney and Bladder Rapid Oral Abstract Session.
The study reports interim results from the phase 2/3 Duravelo-2 trial, evaluating zelenectide pevedotin (BT8009) plus pembrolizumab in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
Abstract Details
- Meeting: 2026 ASCO Annual Meeting
- Session Type: Rapid Oral Abstract Session
- Session: Genitourinary Cancer—Kidney and Bladder
- Citation: J Clin Oncol 44, 2026 (suppl 16; abstr 4516)
- Full Abstract Release: May 21, 2026 (5:00 PM EST)
Study Concept
Duravelo-2 explores a next-generation targeted delivery platform combined with immunotherapy:
- Zelenectide pevedotin → a bicycle toxin conjugate (BTC) targeting Nectin-4, delivering the cytotoxic payload MMAE directly to tumor cells
- Pembrolizumab → restores T-cell–mediated anti-tumor immunity
Bicycle toxin conjugates represent an emerging class of therapeutics characterized by:
- Small size and rapid tumor penetration
- Short plasma half-life, potentially reducing systemic toxicity
- Targeted payload delivery within the tumor microenvironment
Why This Abstract Matters
- Introduces BTCs as a novel alternative to ADCs in urothelial cancer
- Targets Nectin-4, a clinically validated biomarker in urothelial carcinoma
- Explores first-line combination strategies beyond chemotherapy
- Reflects the evolution toward precision delivery + immunotherapy combinations
10 Ongoing Clinical Trials on Immunotherapy in Bladder Cancer
A Phase 2 Trial of IO102-IO103 and Nivolumab–Relatlimab in Previously Untreated, Unresectable Melanoma
This upcoming abstract will be presented by First Author & Presenter James William Smithy, MD, MHS, from Memorial Sloan Kettering Cancer Center, during the Melanoma/Skin Cancers Rapid Oral Abstract Session.
This phase 2 study evaluates a novel immunotherapy combination in patients with previously untreated, unresectable melanoma, integrating a therapeutic cancer vaccine with dual checkpoint blockade.
Abstract Details
- Meeting: 2026 ASCO Annual Meeting
- Session Type: Rapid Oral Abstract Session
- Session: Melanoma/Skin Cancers
- Citation: J Clin Oncol 44, 2026 (suppl 16; abstr 9519)
- Full Abstract Release: May 21, 2026 (5:00 PM EST)
Study Concept
This trial explores a multi-layered immune activation strategy:
- IO102-IO103 → a therapeutic vaccine designed to activate T cells against IDO1 and PD-L1–expressing tumor and immune-suppressive cells
- Nivolumab + Relatlimab → dual checkpoint blockade targeting PD-1 and LAG-3 pathways
The vaccine component aims to expand tumor-specific T-cell responses, while checkpoint inhibition helps sustain and amplify immune activity within the tumor microenvironment.
Why This Abstract Matters
- Introduces cancer vaccines back into the frontline melanoma setting
- Combines innate immune priming + dual checkpoint blockade
- Targets immune-suppressive pathways (IDO1, PD-L1, LAG-3) simultaneously
- Reflects the shift toward multi-mechanistic immunotherapy combinations